Brad Margus has been tapped to co-chair the oversight board for the Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, a new, innovative program at the National Institutes of Health.

NeuroNEXT, will provide a robust, standardized, and expert network of 25 clinical centers across the USA to more quickly test treatments for adults and children with neurological disorders. It promises to alleviate some of the current bottlenecks in the development of new drugs for neurological disorders and could be useful to test promising therapies for A-T.

Oops! We could not locate your form.

Related News

Jun 20 @ 3:27 pm

Art of Nursing Award

A-T Clinic Nurse, Jenny Wright, RN is the recipient of the 2024 Art of Nursing award!

more
Jun 20 @ 3:27 pm

Shining a Light on A-T at the IlluminATion Ball

The A-TCP is hosting IlluminATion: A BioPharma Leadership Ball on May 11 in Boston to shine a light

more
Jun 20 @ 3:27 pm

NEAT Study – Phase 3 Clinical Trial of EryDex, a Low-Dose Steroid

Quince Therapeutics is advancing a phase 3 clinical trial to evaluate EryDex, a potential new treatment for ataxia-telangiectasia

more
Jun 20 @ 3:27 pm

Measles Prevention in A-T: Recommendations from Dr. Lederman

Dr. Lederman of the A-T Clinical Center provides recommendations to keep people with A-T from catching measles.

more